AbbVie Bolsters Immunology Pipeline with $10.9 Billion Apogee Acquisition
The acquisition would add a longer-acting alternative to Dupixent for inflammatory diseases.
/ 4 items
#APGE↓
Apogee Plunges in Premarket: Solid Eczema Drug Results, But Not Good Enough
Apogee stock fell after good but not great eczema drug results; strong data, but investors expected more.
Apogee’s Long-Acting Eczema Shot Keeps Skin Clear with Just 2 Injections a Year
Apogee Therapeutics’ Phase 2 data show zumilokibart maintains strong skin clearance and itch relief in moderate-to-severe eczema for 52 weeks with dosing every 3 or 6 months.
Fairmount Funds Sells $133.5M Stake in Apogee Therapeutics
Apogee Therapeutics stock drops 12% after major investor Fairmount Funds Management sells 1.75 million shares worth $133.5 million, significantly reducing its position.